Clinical Evaluation of CARESTREAM Vue PACS v12.2 MR Perfusion and Diffusion

Carestream Health, Inc. will investigate the imaging performance of the CARESTREAM Vue PACS v12.2 Magnetic Resonance (MR) Perfusion and Diffusion Weighted Imaging ("investigational device") performance. Evaluation of MR Dynamic Susceptibility Contrast-Enhanced Perfusion Weighted Imaging (DSC-Perfusion), MR Diffusion Weighted Imaging (DWI) and MR Diffusion Tensor Imaging (DTI) was compared to the predicate device, the Olea Sphere PACS with Perfusion and DWI Modules. MR DSC-Perfusion of the brain is a method for evaluating blood flow in the brain and producing optimized parametric maps that help visualize this blood flow. MR DWI is a method to evaluate the motion of water molecules within bodily tissues. MR DTI is an extension of DWI that allows extraction of the diffusion tensor. The purpose of this study is to demonstrate equivalent clinical quality between the investigational and predicate devices using a radiologist evaluation of key metrics which are applicable to MR DSC-Perfusion, MR DWI, and MR DTI images.

Inclusion criteria

• Retrospective patient MR DSC-Perfusion cases with subject/patient 18 years of age or older.
• Retrospective patient MR DWI with subject/patient 18 years of age or older.
• Retrospective patient MR DTI cases with subject/patient 18 years of age or older.
• Informed consent is not required if waiver of consent is approved by the hospital IRB/Ethics Committee

Exclusion criteria

• Low quality images, or images that are not clinically acceptable for clinical diagnostic reading as determined by the Principal Investigator
• Subject less than 18 years of age